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Abstract
Streptococcus equi subspecies equi (S. equi) is a clonal, equine host-adapted pathogen of global importance that causes a
suppurative lymphodendopathy of the head and neck, more commonly known as Strangles. The disease is highly prevalent,
can be severe and is highly contagious. Antibiotic treatment is usually ineffective. Live attenuated vaccine strains of S. equi
have shown adverse reactions and they suffer from a short duration of immunity. Thus, a safe and effective vaccine against
S. equi is highly desirable. The bacterium shows only limited genetic diversity and an effective vaccine could confer broad
protection to horses throughout the world. Welsh mountain ponies (n=7) vaccinated with a combination of seven
recombinant S. equi proteins were significantly protected from experimental infection by S. equi, resembling the
spontaneous disease. Vaccinated horses had significantly reduced incidence of lymph node swelling (p=0.0013) lymph
node abscessation (p=0.00001), fewer days of pyrexia (p=0.0001), reduced pathology scoring (p=0.005) and lower
bacterial recovery from lymph nodes (p=0.004) when compared with non-vaccinated horses (n=7). Six of 7 vaccinated
horses were protected whereas all 7 non-vaccinated became infected. The protective antigens consisted of five surface
localized proteins and two IgG endopeptidases. A second vaccination trial (n=7+7), in which the IgG endopeptidases were
omitted, demonstrated only partial protection against S. equi, highlighting an important role for these vaccine components
in establishing a protective immune response. S. equi shares .80% sequence identity with Streptococcus pyogenes. Several
of the components utilized here have counterparts in S. pyogenes, suggesting that our findings have broader implications
for the prevention of infection with this important human pathogen. This is one of only a few demonstrations of protection
from streptococcal infection conferred by a recombinant multi-component subunit vaccine in a natural host.
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Introduction
Access to the genome sequence data of bacterial pathogens
permitting the identification of surface exposed and secreted
proteins has long been anticipated to revolutionize vaccine design,
referred to as reverse vaccinology [1,2]. However, few vaccines
have been taken beyond studies in mouse model systems and
shown to confer protection against challenge infection in the
natural host.
Strangles, caused by Streptococcus equi subsp. equi (S. equi), is
characterized by abscessation of the lymph nodes of the head and
neck of the horse and is of significant welfare and economic
importance. The development of effective preventative vaccines
has been slow. A non-encapsulated strain of S. equi (Pinnacle
IN
TM) has been used as a nasal vaccine against strangles, but has
not been licensed for sale in Europe due to safety concerns. A
second live attenuated vaccine was marketed in Europe [3]
(Equilis StrepE), but was withdrawn in 2007. Safety concerns have
also been raised over the use of Equilis StrepE [4,5]. A safe and
effective vaccine against S. equi is thus highly desired.
S. equi evolved from an ancestral strain of S. equi subsp.
zooepidemicus (S. zooepidemicus). The population of the S. zooepidemicus
group is extremely diverse and consists of at least 218 sequence
types, whereas isolates of S. equi from the USA, Canada, Australia
and Europe are either ST-179 or a single locus variant, ST-151 [6]
(http://pubmlst.org/szooepidemicus/). The limited genetic diver-
sity of S. equi suggests that an effective vaccine could confer broad
protection to horses throughout the world.
We have demonstrated previously that vaccination of Welsh
mountain ponies with EAG [7,8], SclC [9] and CNE [10]
(Trivacc) conferred partial protection against challenge by S. equi
[11]. The amount of nasal discharge, the number of bacteria
recovered from nasal washes and the occurrence of abscess
material (empyema) in guttural pouches, following rupture of
abscesses formed in the retropharyngeal lymph nodes, differed
significantly between the vaccinated group and a non-vaccinated
PLoS Pathogens | www.plospathogens.org 1 September 2009 | Volume 5 | Issue 9 | e1000584control group. However, clinical scoring and mean rectal
temperatures did not differ significantly. This experiment thus
showed that parameters of importance for spreading disease
between horses were reduced significantly, but that the level of
protection in individual horses was limited [11]. Using a set of
seven recombinant proteins (Septavacc), we demonstrate here that
85% protection was obtained.
Results
Choice of antigens and antibody response
Five of the antigens in the Septavacc composition are predicted
to be localized on the surface of S. equi (EAG [7,8], CNE [10],
SclC [12], SEQ0256 and SEQ0402 [13]) through sortase-
mediated attachment to the peptidoglycan cell wall. EAG binds
to albumin, a-2 macroglobulin (A2M) and IgG [8,14]. CNE binds
to collagen [10], and is located within the FimI pilus locus of S. equi
and S. zooepidemicus [13,15]. SclC is a member of a collagen-like
protein family, which in S. equi consists of seven members, each
with a unique N-terminal domain of unknown function [12]. The
proteins encoded by SEQ0256 and SEQ0402 contain features
typical of cell surface anchored proteins and an N-terminal non-
repetitive domain. The N-terminal domains were used in this
study, the functions of which are unknown and neither shows
homology to any characterized protein. The two additional
antigens in Septavacc, IdeE and IdeE2 are IgG endopeptidases,
where IdeE2 has greater activity towards horse IgG. Both IdeE
and IdeE2 are predicted to be secreted [16,17] and IdeE has an
antiphagocytic activity by binding directly to neutrophils [17].
The antigens in Septavacc were selected from a larger antigen
pool based on the level of protection conferred in an experimental
mouse model of strangles. Mice were immunized with recombi-
nant antigens either individually, or in combination, and
subsequently experimentally infected with S. equi. Following
challenge, mice were examined daily for loss of weight and for
nasal colonization in comparison with non-vaccinated controls.
The reproducibility of the model is sufficiently robust to allow
comparison between different experiments. A ranking list based on
the protective efficacy of the different antigens could therefore be
generated (Table 1). Vaccination with FNE, SFS and FNEB did
not result in protection although good antibody titers were
obtained with these antigens [18]. Good immune responses were
obtained to all other antigens with the exception of IdeE2 and all
of these antigens conferred significant protection in mice (Table 1).
Seven Welsh mountain ponies were vaccinated with Septavacc
and an additional seven ponies were given adjuvant only as control
via both the subcutaneous and intranasal routes, followed by
experimental infection with 1610
8 colony forming units (cfu) of S.
equi strain 4047. Antibody responses against the antigens in serum
samples and nasal washes were analyzed by ELISA (Figures 1A, B
Author Summary
Numerous research groups have vaccinated, using recom-
binant antigens, against streptococcal infections in mouse
model systems and shown protection. We have here
demonstrated efficient protective vaccination of the
natural host, the horse, using recombinant antigens.
Streptococcus equi subspecies equi (S. equi) is an equine
host-adapted and highly contagious pathogen of global
importance. Six out of seven Welsh mountain ponies
vaccinated with a combination of seven recombinant S.
equi proteins were protected from experimental infection
as assessed by clinical examination, pyrexia, lymph node
swelling, inflammation, bacterial recovery, and post
mortem examination. The protective antigens consisted
of five surface localized proteins and two endopeptidases
that are specific for IgG; the latter were shown to be of
major importance for efficacy. Several of the antigens used
here have similarities in Streptococcus pyogenes, implying
that our findings are of importance for development of a
vaccine against this important human pathogen.
Table 1. Antigens used to vaccinate mice.
Exp. number Antigen Relative protective efficacy in mouse model Reference to antigen description or use as vaccine
1F N E 2 [37]
2 SFS 2 [38]
3F N E B 2 [18,20]
4E A G + [7,20]
5 CNE + [10,20]
6 SEQ0936, (putative pili) + This study
7 SEQ0944, (pullulanase) + This study
8 SEQ0256 + This study
9I d e E + [16]
10 CNE+EAG ++ [20]
11 SclC ++ [12,20]
12 EAG+SFS+FNE ++ [20]
13 EAG+CNE+SclC ++ [11]
14 IdeE2 +++ [19]
15 IdeE+IdeE2+EAG +++ This study
16 SEQ0402 +++ This study
17 SEQ0256+SEQ0402 +++ This study
Ranking of efficacy on a range from 2 to +++ was based on weight loss and nasal colonization of mice challenged with S. equi after vaccination with indicated antigens.
doi:10.1371/journal.ppat.1000584.t001
Vaccination against S. equi
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responses in nasal washes and in sera had low correlation in
individual ponies (R
2 from 0.01 to 0.28); a pony could respond
well in sera but less so in nasal washing and v.v. This implies the
generation of independent immune responses in mucosa and sera,
possibly as a result of the two routes of immunization employed.
Exudation of IgG from sera to mucosal surfaces presumably also
contributes to mucosal IgG. A high background level of IgG (in
pre immune sera) against IdeE is presumably due to non-
immunologic binding to IdeE. IgA responses in nasal washes
against SEQ0256, SEQ0402, IdeE and IdeE2 were moderate but
significant for SEQ0402, IdeE and IdeE2 with p values 0.04, 0.02
and 0.05 respectively.
In a separate study, seven ponies were immunized with a
Pentavacc formulation, containing the same five surface antigens
as Septavacc, but with the omission of IdeE and IdeE2. Serum
samples and nasal washes were taken every month. Significantly
elevated IgG levels to the five surface proteins could be detected 6
months post V3 and an additional booster (V4) on day 270 led to a
rapid increase of IgG in sera against all antigens (Figure 2A). IgG
against the antigens in nasal washes also persisted for a long time
as shown in Figure 2B.
Sera from Septavacc vaccinated ponies were also tested for the
ability to inhibit the IgG cleaving activity of IdeE and IdeE2. Sera
pooled from ponies immunised with Septavacc could be diluted 16
fold and still inhibit the cleavage of human IgG by IdeE. The
inhibitory activity against IdeE2 cleavage was much less. At a 2
fold serum dilution the cleavage of horse IgG was inhibited
(Figure 3A and B). Neither pre-immune sera from the Septavacc
vaccinated ponies nor sera from Pentavacc vaccinated ponies had
any effect on the IgG cleavage activity of IdeE or IdeE2 (data not
shown).
Clinical assessment of infection
The swelling and abscessation of submandibular lymph nodes is
a typical clinical sign of infection with S. equi. The mean lymph
node scores in Septavacc vaccinated ponies differed from the
control group and the number of days where an individual pony’s
score exceeded 2, differed significantly (p=0.0013) (Figure 4).
The normal rectal temperature of Welsh mountain ponies is 37–
38uC and a pony with a rectal temperature of 39uC or higher is
considered pyrexic. All ponies in the control group became pyrexic
at some stage during challenge compared to only one pony in the
Septavacc vaccinated group. The accumulated number of days
that individual ponies in the vaccinated or control groups were
pyrexic was 5 and 30 days, respectively (p=0.0001) (Figure 5).
Infection withS. equi leads to a systemic inflammation, manifested
asanincrease inbloodfibrinogen and neutrophillevels.Asshownin
Figure 6A and B, fibrinogen and neutrophil levels of ponies
vaccinated with Septavacc remained normal, whereas the non-
vaccinated group had significantly higher mean values.
Ponies vaccinated with Pentavacc, containing the same antigens
as in Septavacc but omitting the IgG endopeptidases, were
challenged 14 days after the last booster. These ponies differed
from the corresponding control group in terms of elevated
temperature, fibrinogen levels and nasal discharge, but not
significantly so. One pony was protected fully.
Post mortem scoring
To minimize suffering and in accordance with our strict ethical
and welfare code, ponies were euthanized as soon as clinical signs
of S. equi infection became apparent. All of the control ponies were
euthanized between 8 to 12 days post challenge. Vaccinated
ponies, however, had reduced clinical signs and all ponies reached
the end of the study, 21 days post challenge. Following euthanasia,
all of the ponies were subject to post mortem examination to
quantify the level of pathology observed using a scoring system as
described in Materials and Methods.
Figure 7 summarizes the individual post mortem scores of
ponies vaccinated with Trivacc (EAG, SclC, CNE) [11], Pentavacc
and Septavacc, containing three, five and seven antigens
respectively. Increasing the number of antigens comprising each
vaccine significantly reduced the post mortem score. Only one of
Figure 1. Determination of antibody titers in ponies vaccinated
with Septavacc. Serum samples (A) and nasal washes (B) were taken
from vaccinated ponies before immunization (white bars) or 12 days
after third immunization (dark grey bars). Serum samples were also
taken 11 days after second vaccination (light grey bars in panel a).
Microtiter plates were coated with indicated antigens and ELISA was
performed as described earlier [7]. The dilutions required to obtain an
absorbance of 1.0 for nasal wash samples and 1.5 for sera were
calculated; the titration curves are linear and parallel at these values.
The average and standard error of the mean (SEM) of log values of
these dilutions are plotted. All increases of IgG titers are significant. IgA
was determined using nasal washes diluted 2-fold and the absorbance
value plotted; white bars before immunization and grey bars after third
vaccination (C).
doi:10.1371/journal.ppat.1000584.g001
Vaccination against S. equi
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compared with abscesses in all seven non-vaccinated ponies. To
confirm these gross pathological findings, samples from ponies
vaccinated with Septavacc were examined histopathologically and
scored using a system as described in Materials and Methods.
Again, significant differences were seen between the Septavacc
and control groups (p=0.006) (Figure 8). Histopathological
examination of the left and right retropharyngeal and subman-
dibular lymph nodes identified 19 lymph node abscesses in the
control ponies and 3 lymph node abscesses in a single pony in the
Septavacc group (p=0.00001). Seventy-eight and 10% of all
lymph nodes were culture positive for S. equi in the control and
vaccine groups respectively (p=0.004).
Discussion
Taking all of the results together, vaccination with Septavacc
resulted in 85% protection from disease, with only one vaccinated
pony out of seven developing lymph node abscesses.
This study is one of only a few demonstrations of protection in a
natural host from streptococcal infection conferred by a recom-
binant multi-component subunit vaccine. No significant adverse
effects were seen in any of the vaccinated ponies, demonstrating
that both the recombinant antigens and the adjuvant were safe. It
is also clear that the antiphagocytic capsule and other immune
evasion mechanisms employed by S. equi were not sufficient to
counter successful vaccination with the recombinant proteins used
here. The approach taken here is significantly safer than currently
available live attenuated strains of S. equi.
The large difference in efficacy between Pentavacc and
Septavacc (p=0.036 for post mortem scoring), suggests that the
inclusion of one or both of the endopeptidases IdeE and IdeE2 is
important for protection in the natural host. As antibodies in sera
from the Septavacc vaccinated ponies can inhibit the IgG cleaving
activities of IdeE and IdeE2, it is conceivable that these antibodies
prevent the destruction of antibodies directed against the other five
components in Septavacc .We have recently found that immuni-
zation of mice with IdeE and IdeE2 as single antigens confer
Figure 2. Determination of antibody titers in ponies vaccinated with Pentavacc. ELISA was performed and values calculated as in Figure 1
showing average and SEM. Serum samples (A) were taken on days 1, 71, 86, 127, 155, 183, 211, 239, 281, and 288 shown by gradually darker bars.
Immunizations were given on days 4, 60, 74, and 270 and challenge on day 284. The white bar is thus from pre-immunization sample and the last
black bar from 4 days after challenge. Comparison of titers from pre-immunization (day 1) and the last before V4 (day 239) gives p-values of 0.0002,
0.0001, 0.010, 0.014, and 0.0001 for the five antigens. Nasal wash samples (B) were taken on days 1, 127, 239 and 281 (white, light grey, dark grey and
black bars respectively). Comparison of titers from pre-immunization (day 1) and before V4 (day 239) gives p-values of 0.08, 0.01, 0.036, 0.001, and
0.0006 for the five antigens.
doi:10.1371/journal.ppat.1000584.g002
Vaccination against S. equi
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effect might be due to opsonising antibodies targeting IdeE and
IdeE2 during the secretion process. It cannot be ruled out that the
difference in efficacy between Pentavacc and Septavacc might also
be attributed to the different vaccination schedules. The ponies
vaccinated with Pentavacc were infected 6.5 months later than
those vaccinated with Septavacc but were therefore given an
additional booster (V4) two weeks before challenge. After this
booster, antibody titers in these ponies reached the same level as in
ponies vaccinated with Septavacc. With the exception of IdeE and
IdeE2, the contribution of each protein to the protective activity of
Septavacc has not been addressed in this study. Neither have we
attempted to analyze in depth the mechanism of action of the
protective antibodies. The activity of antibodies against surface
localized antigens might de dual: adherence blocking and opsonic.
We have previously found that antibodies against CNE effectively
block adherence of S. equi to collagen [20].
With the exception of the 59 variable region of SeM [21] the
genomic variation between isolates of S. equi is thought to be
minimal and all strains analyzed to date by MLST are either ST-
179 or the single locus variant ST-151. The antigens used in this
study were all cloned from the Swedish S. equi strain 1866, which is
SeM type-9, whilst the S. equi strain 4047 challenge strain is SeM
type-3 and was isolated in the UK. Therefore, it is likely that the
antigens present in Septavacc will confer broad protection against
S. equi strains from around the world.
S. equi shares .80% sequence identity with Streptococcus pyogenes
[13] and several components utilized in our studies share similarity
with S. pyogenes antigens, either by homology or function. The S.
pyogenes gene encoding the collagen binding protein Cpa is located
in the variable FCT region (fibronectin- and collagen-binding T-
antigen) and is part of a pilus-like structure [22]. Similarly, cne is
Figure 3. SDS-PAGE of IgG cleavage with endopeptidase IdeE and IdeE2. (A) IdeE cleavage of human IgG in the presence of serum from
Septavacc vaccinated ponies and (B) IdeE2 cleavage of horse IgG in the presence of serum from Septavacc vaccinated ponies. (A) Lane 1; Septavacc
diluted 4 times, lane 2; Septavacc serum diluted 8 times, lane 3; Septavacc serum diluted 16 times, lane 4; Septavacc serum diluted 32 times, lane 5;
Septavacc serum diluted 64 times, lane 6; human IgG+IdeE, lane 7; human IgG, lane 8; size marker (in kDa 97, 66, 45, 30, 20, 14,4). The same amount of
IdeE is added to sample 1–6 and the same amount of human IgG is added to sample 1–7. (B) Lane 1; Septavacc undiluted, lane 2; Septavacc diluted 2
times, lane 3; Septavacc diluted 4 times, lane 4; Septavacc diluted 8 times, lane 5; Septavacc diluted 16 times, lane 6; horse IgG+IdeE2, lane 7; horse
IgG, lane 8; size marker. The same amount of IdeE2 was added to sample 1–6 and the same amount of horse IgG was added to sample 1–7. The
arrows just above the 30 kDa band indicate the cleavage product of IgG.
doi:10.1371/journal.ppat.1000584.g003
Figure 4. Lymph node swelling over time in Septavacc and
control ponies. Lymph node swelling was monitored from three days
pre-challenge (day 85) using an arbitrary scale from 0 to 4. Average
values and SEM are shown. The insert shows number of days each pony
was considered positive, i.e. with a value exceeding 2. P-value in insert:
*p=0.05. Non-vaccinated (open symbols) (n=7) and Septavacc
vaccinated (closed symbols) (n=7).
doi:10.1371/journal.ppat.1000584.g004
Figure 5. Temperature over time in Septavacc and control
ponies. Mean rectal temperature was monitored from three days pre-
challenge (day 85). Average values and SEM are shown. The insert
shows number of days each pony was considered pyrexic, i.e. with a
temperature exceeding 39.0uC. P-value in insert: **p=0.01. Non-
vaccinated (open symbols) (n=7) and Septavacc vaccinated (closed
symbols) (n=7).
doi:10.1371/journal.ppat.1000584.g005
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and a putative backbone pilus subunit suggesting that CNE is also
attached to a pilus-like structure [13]. EAG, like GRAB from S.
pyogenes, binds the proteinase inhibitor A2M [8,23,24]. SclC is one
of seven collagen-like surface proteins in S. equi, whilst S. pyogenes
genomes contain two such putative proteins, SclA and SclB [9].
The IgG-specific endopeptidases used here, IdeE and IdeE2 [19],
are similar both in function and amino acid sequence to IdeS/
Mac/sib35 of S. pyogenes [16,17,25,26]. Antibodies against IdeS in
convalescent patients were able to neutralize its function [27].
Interestingly, Cpa (plus other pili components) and Sib35 have
been identified as protective antigens in mouse models of S. pyogenes
infection. The Cpa combination and Sib35 gave good protection
in a mouse system whereas antibodies against GRAB could only
opsonize capsule-deficient mutants of S. pyogenes [28–30]. Thus, it
is conceivable that vaccination of humans with a combination of S.
pyogenes antigens similar to the ones used in Septavacc could prove
effective against this important human pathogen
In a study by Timoney et al., [31] two combinations of
recombinant proteins derived from S. equi (SzPSe, CNE, Se51.9,
Se44.2 and Se46.8 or SeM, Se44.2, Se75.3, Se42.0, Se110.0 and
Se18.9) were tested as vaccines against strangles. However, neither
combination protected horses from infection with S. equi [31]. Two
of these proteins CNE and IdeE2 (Se44.2) are included in the
Septavacc vaccine, suggesting that the additional components of
Septavacc are important in generating a protective immune
response. It was also suggested that an effective strangles vaccine
should result in immune-mediated tonsillar clearance since
tonsillar adherence is a crucial early step in the pathogenesis of
strangles [31,32]. If this is the case, the route of immunization and
choice of adjuvant, which differ between these studies, might be of
utmost importance. We have generally noted that mice immu-
nized by the intranasal route are far better protected than those
immunized subcutaneously. IgA responses in nasal washes were
obtained in this study. It is likely that the ability to block bacterial
adherence to mucosal surfaces is of importance to the protection
observed in this study. A good mucosal immune response was
obtained in the mouse by using nanospheres to which S. equi
proteins, extracted from the bacterial wall, were adsorbed [33,34].
The poorer efficacy observed with Trivacc could be due, not only
to fewer antigens, but also to the fact that immunizations were
Figure 6. Inflammatory markers over time in Septavacc and
control ponies. Neutrophil counts (A) and fibrinogen levels (B) were
monitored from two days pre-challenge (day 86). Average values and
SEM are shown. P-values: **p=0.002, ***p=0.0004 in (a), *p=0.024,
**p=0.002 in (B). Non-vaccinated (open symbols) (n=7) and Septavacc
vaccinated (closed symbols) (n=7).
doi:10.1371/journal.ppat.1000584.g006
Figure 7. Post mortem score. Ponies were vaccinated with three
different antigen combinations, (Trivacc, Pentavacc and Septavacc)
followed by challenge with S. equi. Post mortem scoring was performed
using a scoring system described in Materials and Methods. Non-
vaccinated (open symbols) and vaccinated (closed symbols) for
individual ponies and median values are shown. Mann Whitney test
was used to calculate significance.
doi:10.1371/journal.ppat.1000584.g007
Figure 8. Histopathological examinations of Septavacc and
control ponies. Evaluation was done using the scoring system
described in Materials and Methods. Non-vaccinated (open symbols)
and vaccinated (closed symbols) for individual ponies and median
values are shown. Mann Whitney test was used to calculate significance.
doi:10.1371/journal.ppat.1000584.g008
Vaccination against S. equi
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both subcutaneous, near the retropharyngeal lymph node, and i.n.
The necessity of both routes of immunizations will be determined
in future studies.
In conclusion, we have demonstrated that using recombinant
antigens, a protective immune response against a streptococcal
infection can be obtained in the natural host, not just in a mouse
model system. Immune protection by vaccination does not
necessarily require an attenuated live vaccine or vaccination with
killed bacteria, conventional strategies for vaccine design.
Materials and Methods
Ethics statement
Approval for mice experiments was obtained from Swedish
Animal Welfare Agency. The pony studies were conducted under
a Home Office Project License. The Animal Health Trust Ethical
Review Committee approved the Research Program Proposal for
these studies.
Bacterial strains, plasmids and growth conditions
S. equi strain 1866 SeM type-9 (obtained from Nordvacc
La ¨kemedel AB, Sweden) was used as source DNA for cloning the
antigens and used as the challenge strain in mouse infection
experiments. The S. equi strain 4047, SeM type-3 was isolated from
a case of strangles (Animal Health Trust), was used as the
challenge strain in horse infection experiments. To clone and
express the recombinant antigens, SEQ0256, SEQ0402,
SEQ0944, SEQ0936, and IdeE2, the E. coli strains ER2566 or
BL21(DE3) and plasmid vector pTYB4, belonging to the
IMPACT
TM Protein Purification System (New England Biolabs
Inc., MA) were used. The E. coli strain BL21(DE3) and plasmid
vector pGEX-6P-1 belonging to GST-glutathione affinity system
(GE Healthcare) were used to clone and express IdeE. Plasmids
and PCR amplified DNA fragments were purified using the
QIAprep Spin Miniprep (Qiagen, Hilden, Germany).
Strains of S. equi were grown on blood agar plates or in Todd-
Hewitt broth (Oxoid, Basingstoke, Hampshire, United Kingdom)
and E. coli clones were cultured in Luria-Bertani (LB) broth,
supplemented with ampicillin (50 mg/ml), or on LAA plates [LB-
broth with ampicillin and agar (15 g/L)]. Incubations were at 37uC
unless otherwise stated.
Construction of clones
The S. equi strain 4047 genome database (www.sanger.ac.uk/)
was analyzed to select open reading frames encoding a number of
extra cellular proteins to be tested as potential antigens in the
vaccination trials. To identify the predicted signal sequences, the
computer program SignalP (http://www.cbs.dtu.dk/services/Sig-
nalP/) was used.
Chromosomal DNA from S. equi strain 1866 was used as a
template to PCR amplify the genes (or part of the genes) encoding
SEQ0256, SEQ0402, SEQ0944, SEQ0936, IdeE, and IdeE2. The
sequences of primers used are listed in Table 2. Cleavage sites for
restriction enzymes were included in the primer sequences to
match the cloning sites in the plasmid vectors. The PCR
amplifications were performed using the primers (20 pmol/ml)
and ReadyToGo
TM PCR beads (GE Healthcare) using a standard
PCR programme (Step 1, pre-heat 1 minute at 95uC, DNA strand
separation; Step 2, 30 seconds at 95uC; Step 3, annealing
15 seconds at usually 5 degree below the melting temperature;
and Step 4, elongation for 2 minutes at 72uC, Steps 2–4 were run
for 30 cycles.) The PCR products were analyzed on an agarose gel,
and thereafter purified using the QIAquick PCR Purification
Kit
TM (Qiagen). After restriction enzyme cleavage the fragments
were purified again using the kit mentioned above before ligation
into the respective vector using the ReadyToGo T4DNA Ligase
(GE Healthcare). After ligation, the samples were transformed into
competent E. coli strain ER2566 or BL21(DE3) using electropo-
ration, spread on LAA plates and incubated over night at 37uC.
Next day, a number of colonies were analyzed by PCR for the
presence of inserts, using the respective primer combination.
Clones with correct inserts were further analyzed by DNA
sequencing.
Production of recombinant antigens
To produce and purify the recombinant proteins SEQ0256,
SEQ0402, SEQ0936, SEQ0944, [13] and IdeE2, the expression
and purification system IMPACT
TM T7 (NEB) was used. Briefly,
following the manufacturer’s instructions the clones containing the
Table 2. The primer sequences used to PCR amplify the genes seq0936, seq0944, seq0256, seq0402, ideE2 and IdeE2.
Gene Corresponding part in protein Primer name Sequence
seq0936 1–422 Eqp541 GCATCCATGGATACAGCAAGCTATACCA
Eqp542 TCGACTCGAGGATAGACCCTTTTTTATTAAC
seq0944 1–427 Eqp271 GCAGCCATGGAGAGTCTGACGAGTGTTGA
Eqp272 TCACCTCGAGTCCTAGCTCACCGTCATAAGC
seq0256 1–441 Eqp51 GTAGCCATGGAAACGACTACTGCTAGTGCA
Eqp52 CTGGCTCGAGCGGTTTAGCAACCAAGGCT
seq0402 1–196 Eqp81 CATGCCATGGCGACTACCCTAGCAGGACAAA
Eqp82 CTAGCTCGAGGTGCTTAAGCTTTTCAATCTG
IdeE 1–315 IdeG1 TACTGGATCCGACGATTACCAAAGGAATGCTAC
IdeG2 TGATCTCGAGTTAGCTCAGTTTCTGCCATATG
IdeE2 1–344 Ide2F CATGCCATGGAGGTAGTTGAAGTTTGGCCTAAT
Ide2R CCGCTCGAGTTTTTCTGTGTTGTTGAAGTAATCTGC
The bold nucleotides correspond to the introduced restriction cleavage sites. The number indicated in the corresponding protein refers to amino acids in the mature
protein.
doi:10.1371/journal.ppat.1000584.t002
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supplemented with ampicillin (final conc. 50 mg/ml). At an optical
density (OD600 nm),0.6, the growth media were supplemented
with IPTG (final conc. 0.3 mM) and the growth temperature
shifted to 20uC. After incubation over night the cells were
harvested and resuspended in a buffer [20 mM Tris-HCl (pH 8.0),
500 mM NaCl, 0.1 mM EDTA, and 0.05% (v/v) TWEEN20]
and lysed by freezing and thawing. After centrifugation, the
supernatants were sterile filtrated and applied onto a chitin
column. The columns were washed extensively using the same
buffer and treated subsequently with cleavage buffer [20 mM Tris-
HCl (pH 8.0), 50 mM NaCl, 0.1 mM EDTA, and 30 mM
dithiothreitol (DTT)]. The eluted samples containing the antigens
were dialysed against phosphate-buffered saline [PBS; 137 mM
NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.4 mM KH2PO4
(pH 7.4)].
Recombinant IdeE was produced using the GST-glutathione
affinity system. Briefly, according to the procedure described
above, after growth, induction and harvest, the E. coli cells were
suspended in PBS supplemented with TWEEN20, final conc.
0.1% (v/v) (PBST) whereupon the cells were lysed by freezing and
thawing. After centrifugation, the supernatant was sterile filtrated
and batch purified with Glutathione-sepharose beads. After
extensive washing using PBST the fusion protein was treated with
scissor protease to release IdeE. Finally, the amounts of antigens
obtained were determined using spectrophotometry and the
quality analyzed by SDS-PAGE coomassie staining. The proteins
were stored finally at 220uC. IdeE and IdeE2 were produced as
full-length protein with a few extra amino acids from the vectors
and both proteins showed IgG-cleaving activity. It should be noted
that IdeE2 had a tendency to partially precipitate upon freezing.
The production of EAG, SclC and CNE has been described
previously [11].
IgG cleaving activity by IdeE and IdeE2
The cleaving activity of IdeE was assayed against human IgG
(Bethyl Laboratories inc., Montgomery, TX) whereas the IdeE2
activity was measured against horse IgG (Bethyl Laboratories inc.,
Montgomery, TX). Before cleavage, DTT was added to the
endopeptidases to a final concentration of 0.5 mM. Thereafter the
enzymes were added to IgG (1 mg/ml) for 30–60 minutes and
cleavage was visualised by coomassie blue staining of SDS-PAGE
gels.
To test for inhibitory activity of sera against the endopeptidases
the same type of assay as above was used. Briefly, Septavacc sera
from six ponies were pooled and diluted in steps of two. As
controls, pre-immune Septavacc sera and Pentavacc sera were also
pooled and diluted. The assay was performed by mixing 2 mlo f
either endopeptidase (15 mg/ml) separately with 2 ml of diluted
sera for 15 min in room temperature after which 8 ml of IgG
(1 mg/ml) was added and incubated for 45 minutes at 37uC and
the samples analysed on SDS-PAGE.
Mouse model of strangles
Prior to experimental challenge infection, female NMRI mice
(n=15) were vaccinated with recombinant proteins derived from
S. equi as described earlier [20]: 12 mg of each antigen and 10 mgo f
adjuvant (Abisco 300, Isconova, Uppsala, Sweden [35]) were given
intranasally on days 1, 14 and 21. Control mice (n=15) were
given adjuvant only. Blood samples were collected for assessment
of antibody titers in ELISA [20].
Infection of mice with S. equi strain 1866 was performed 7 days
after the final booster as described previously [20]. Briefly, 10
6 CFU
of S. equi strain 1866 (cultivated in THB+10% horse serum+1%
yeast extract for 4 hours in a 5% CO2 enriched atmosphere) were
given intranasally to anesthetized mice. Weight loss and coloniza-
tion of nostrils were followed daily. Blood agar plates containing
gentiana violet, to select for streptococcal growth, were placed
gently onto the nostrils. Bacteria were spread out on the plates,
which were then incubated overnight in a 5% CO2 enriched
atmosphere. A scoring system was used where 0–5 colonies=0, 5–
100=1, .100 colonies=2 and confluent growth=3.
Immunization of ponies
Healthy Welsh Mountain Ponies (n=7) were vaccinated with
Septavacc via administration of 1 ml subcutaneous (s.c.) injections
bilaterally close to the retropharyngeal lymph nodes and 2 ml
intranasally (i.n.) by spraying into each nostril on days 4, 60, and
74 (V1, V2 and V3). The Septavacc vaccine doses contained
150 mg for i.n. and 50 mg for s.c. injections of each antigen (EAG,
CNE, SclC, SEQ0256, SEQ0402, IdeE, and IdeE2). Abisco 300
(Isconova, Uppsala, Sweden [35]) (500 mg per i.n. dose) and
Abisco 200 (375 mg per s.c. dose) were used as adjuvants.
Septavacc ponies were challenged on day 88. Pentavacc
vaccinated ponies (n=7) followed the same vaccination protocol
as above, but were given an additional booster vaccination (V4) on
day 270 and challenged on day 284. Negative control ponies were
given adjuvant only, mixed with PBS (n=7). Sera and nasal
washes were taken regularly to quantify IgG responses by ELISA
[11]. IgA was determined in nasal washes at a 2-fold dilution,
using mouse anti horse-IgA monoclonal antibody (Serotec,
Oxford, UK) followed by rabbit anti mouse-IgG HRP conjugated
antibodies for detection (Dako, Denmark).
Experimental infection of ponies
Ponies were transferred to a containment unit three days before
challenge. Two weeks after the final booster immunization, each
pony was challenged with S. equi strain 4047 administered via the
spraying of a 2 ml culture containing 5610
7 cfu into each nostril.
Bacteria were grown overnight in Todd Hewitt broth and 10%
fetal calf serum (THBS) in a 5% carbon dioxide enriched
atmosphere at 37uC, diluted 40-fold in fresh pre-warmed THBS,
further cultivated and harvested at an OD=0.3. This infection
dose has been shown to optimize the infection rate, whilst avoiding
overwhelming the host immune response, as determined in
previous studies [11,36].
Clinical evaluation of and sampling from ponies
Ponies were monitored for the onset of clinical signs of disease
over a period of three weeks post challenge by daily physical
examination, rectal temperature, lymph node swelling and nasal
discharge scoring. Blood samples were taken for evaluation of
fibrinogen concentration as described in [11] and neutrophil levels
by total white blood count performed on Beckman-Coulter
ACTdiff analyzer with a manual differential count to calculate
% neutrophils.
The level of swelling of SMLNs was defined as 0=normal,
1=slight swelling, 2=moderate swelling, 3=severe swelling and
4=abscessated [11]. Bilateral swelling of submandibular lymph
nodes was scored separately
Post mortem examination
Post mortem examination was performed on all ponies
following the onset of clinical signs of infection or on reaching
the study endpoint at 3 weeks post challenge. The severity of
disease pathology was quantified according to a scoring system
described previously [11]. The severity of disease on histopatho-
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system: empyema of guttural pouch 5, lymph node abscessation 5,
pharyngitis 1, lymphadenitis 1, and rhinitis 1.
Statistics
Fischer’s exact test was used for comparison of values from
arbitrary scoring using a cut-off value splitting the group into
‘‘low/negative’’ or ‘‘high/positive’’. Cut-off values were for nasal
colonization in mice 1.5; for lymph node scoring 2; for pyrexia
39uC. Mann Whitney test was used for post mortem and
histopathology scoring in ponies. T-test was used to compare
temperatures, fibrinogen and neutrophil levels in ponies and
weight loss in mice.
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